Gene therapy and tissue engineering for sports medicine

Journal of Gene Medicine

Volumn 5, Issue 2, 2003, Pages 93-108

  Huard, Johnny ^a,b   Li, Yong ^a   Peng, Hairong ^a   Fu, Freddie H ^a  

^a CHILDREN S HOSPITAL OF PITTSBURGH   (United States)

^b UNIVERSITY OF PITTSBURGH   (United States)

Author keywords

Gene therapy; Growth factor; Sports injury; Tissue engineering

Indexed keywords

ACIDIC FIBROBLAST GROWTH FACTOR; ANTIBIOTIC AGENT; BASIC FIBROBLAST GROWTH FACTOR; BETA GALACTOSIDASE; BIOPOLYMER; BONE MORPHOGENETIC PROTEIN 2; BONE MORPHOGENETIC PROTEIN 4; CYCLOPHOSPHAMIDE; EPIDERMAL GROWTH FACTOR; FIBROBLAST GROWTH FACTOR 2; FUMAGILLOL CHLOROACETYLCARBAMATE; GAMMA INTERFERON; GROWTH FACTOR; HYALURONIC ACID; LIM PROTEIN; LIPOSOME; NERVE GROWTH FACTOR; OSTEOGENIC PROTEIN 1; PARATHYROID HORMONE[1-34]; PLASMID DNA; PLATELET DERIVED GROWTH FACTOR; PLATELET DERIVED GROWTH FACTOR AA; PLATELET DERIVED GROWTH FACTOR AB; PLATELET DERIVED GROWTH FACTOR BB; RECOMBINANT PROTEIN; SOMATOMEDIN C; SURAMIN; TRANSFORMING GROWTH FACTOR BETA1; UNINDEXED DRUG; VASCULOTROPIN; VIRUS VECTOR; GROWTH PROMOTOR;

CARTILAGE DEGENERATION; CLINICAL TRIAL; DRUG ACTIVITY; DRUG POTENTIATION; EX VIVO STUDY; FRACTURE NONUNION; GENE EXPRESSION; GENE TARGETING; GENE TRANSFER; GENE VECTOR; HEALING; HUMAN; IN VIVO STUDY; KNEE MENISCUS RUPTURE; LIGAMENT RUPTURE; MUSCLE INJURY; NONHUMAN; NONVIRAL GENE DELIVERY SYSTEM; NONVIRAL GENE THERAPY; PRIORITY JOURNAL; PROTEIN FUNCTION; REVIEW; SPORT INJURY; SPORTS MEDICINE; TENDON RUPTURE; TISSUE ENGINEERING; VIRAL GENE DELIVERY SYSTEM; VIRAL GENE THERAPY; ARTICULAR CARTILAGE; BONE; GENE THERAPY; LIGAMENT; METABOLISM; METHODOLOGY; PHYSIOLOGY; SKELETAL MUSCLE; TENDON;

ATHLETIC INJURIES; BONE AND BONES; CARTILAGE, ARTICULAR; GENE THERAPY; GENETIC VECTORS; GROWTH SUBSTANCES; HUMANS; LIGAMENTS; MUSCLE, SKELETAL; SPORTS MEDICINE; TENDONS; TISSUE ENGINEERING;

EID: 0346906569     PISSN: 1099498X     EISSN: None     Source Type: Journal    
DOI: 10.1002/jgm.344     Document Type: Review

References (230)

1. Trippel S. Growth factors as therapeutic agents. Instr Course Lect 1997; 46: 473-476.
2. Collier S, Ghosh P. Effects of transforming growth factor beta on proteoglycan synthesis by cell and explant cultures derived from the knee joint meniscus. Osteoarthritis Cartilage 1995; 3: 127-138.
3. Schmidt C, Georgescu H, Kwoh C, et al. Effect of growth factors on the proliferation of fibroblasts from the medial collateral and anterior cruciate ligaments. J Orthop Res 1995; 13: 184-190.
4. Hannallah D, Petersen B, Lieberman J, Fu F, Huard J. Gene therapy in orthopaedic surgery. J Bone Joint Surg Am. 2002; in press.
5. Robbins P, Ghivizzani S. Viral vectors for gene therapy. Pharmacol Ther 1998; 80: 35-47.
6. Evans C, Robbins P. Possible orthopaedic applications of gene therapy. J Bone Joint Surg Am 1995; 77: 1103-1114.
7. Gospodarowicz D, Cheng J. Heparin protects basic and acidic FGF from inactivation. J Cell Physiol 1986; 128: 475-484.
8. Mitchell C, McGeachie J, Grounds M. The exogenous administration of basic fibroblast growth factor to regenerating skeletal muscle in mice does not enhance the process of regeneration. Growth Factors 1996; 13: 37-55.
9. Mulligan R. The basic science of gene therapy. Science 1993; 260: 926-932.
10. Siegel M, Roberts C. Meniscal allografts. Clin Sports Med 1993; 12: 59-80.
11. Indelicato P, Linton R, Huegel M. The results of fresh-frozen patellar tendon allografts for chronic anterior cruciate ligament deficiency of the knee. Am J Sports Med 1992; 20: 118-121.
12. Aglietti P, Buzzi R, D'Andria S, et al. Patellofemoral problems after intraarticular anterior cruciate ligament reconstruction. Clin Orthop 1993; 288: 195-204.
13. Marks P, Cameron M, Fu F. [Reconstruction of the cruciate ligaments with allogeneic transplants. Techniques, results and perspectives] German. Orthopade 1993; 22: 386-391.
14. Stone K, Steadman J, Rodkey W, et al. Regeneration of meniscal cartilage with use of a collagen scaffold. Analysis of preliminary data. J Bone Joint Surg Am 1997; 79: 1770-1777.
15. Crystal R. Transfer of genes to humans: early lessons and obstacles to success. Science 1995; 270: 404-410.
16. Solchaga L, Dennis J, Goldberg V, et al. Hyaluronic acid-based polymers as cell carriers for tissue-engineered repair of bone and cartilage. J Orthop Res 1999; 17: 205-213.
17. Wright V, Peng H, Huard J. Muscle based gene therapy and tissue engineering for the musculoskeletal system. Drug Discov Today 2001; 6: 728-733.
18. Martinek V, Fu F, Huard J. Gene therapy and tissue engineering in sports medicine. The Physician in Sports Medicine 2000; 28: 34-51.
19. Musgrave D, Fu F, Huard J. Perspectives on modern orthopaedics. Gene therapy and tissue engineering in orthopaedic surgery. J Am Acad Orthop Surg 2002; 10: 6-15.
20. Picciolo G. Enabling biomaterials technology for tissue engineering: Introduction. Tissue Eng 1997; 3: 67-70.
21. Minsk A. "Come out, come out wherever you are": the Food and Drug Administration's proposed rule on establishment registration and listing for manufacturing of human cellular and tissue-based products. Tissue Eng 1998; 4: 445-446.
22. Sakou T. Bone morphogenetic proteins: from basic studies to clinical approaches. Bone 1998; 22: 591-603.
23. Day C, Bosch P, Kasemkijwattana C, et al. The use of muscle cells to mediate gene transfer to the bone defect. Tissue Eng 1999; 5: 119-125.
24. O'Driscoll S. The healing and regeneration of articular cartilage. J Bone Joint Surg Am 1998; 80: 1795-1812.
25. Dunn M. Tissue engineering strategies for ligament reconstruction. Mater Res Soc 1996; 21: 43-46.
26. Lehto M, Jarvinen M. Muscle injuries, their healing process and treatment. Ann Chir Gynaecol 1991; 80: 102-108.
27. Garnett WE, Best TM. Anatomy, physiology and mechanics. In Orthopaedic Basic Science, Simon S (ed). American Academy of Orthopaedic Surgeons: Rosemont, 1994; 89-125.
28. Crisco J, Jolk P, Heinen G, et al. A muscle contusion injury model, biomechanics, physiology and histology. Am J Sports Med 1994; 22: 702-710.
29. Fukushima K, Badlani N, Usas A, et al. The use of anti-fibrosis agent to improve muscle recovery after laceration. Am J Sports Med 2001; 29: 394-402.
30. Garrett W, Saeber A, Boswick J, et al. Recovery of skeletal muscle after laceration and repair. J Hand Surg Am 1984; 9A: 683-692.
31. Garrett W. Muscle strain injuries: clinical and basic aspects. Med Sci Sports Exercise 1990; 22: 436-443.
32. Hughes C, Hasselman C, Best T, et al. Incomplete, intrasubstance strain injuries of the rectus femoris muscle. Am J Sports Med 1995; 23: 500-506.
33. Jarvinen M, Sorvari T. Healing of a crush injury in rat striated muscle. 1. Description and testing of a new method of inducing a standard injury to the calf muscles. Acta Pathol Microbiol Scand 1975; 83A: 259-265.
34. Kasemkijwattana C, Menetrey J, Day C, et al. Biological interventions in muscle healing and regeneration. Sports Med Arthrosc Rev 1998; 6: 95-102.
35. Kasemkijwattana C, Menetrey J, Somogyi G, et al. Development of approaches to improve the healing following muscle contusion. Cell Transplant 1998; 7: 585-598.
36. Kasemkijwattana C, Menetrey J, Bosch P, et al. Use of growth factors to improve muscle healing after strain injury. Clin Orthop 2000; 370: 272-285.
37. Lee C, Fukushima K, Usas A, et al. Biological intervention based on cell and gene therapy to improve muscle healing following laceration. J Musculoskel Res 2000; 4: 265-277.
38. Menetrey J, Kasemkijwattana C, Fu F, et al. Suturing versus immobilization of a muscle laceration: a morphological and functional study in a mouse model. Am J Sports Med 1999; 27: 222-229.
39. Menetrey J, Kasemkijwattana C, Day C, et al. Growth factors improve muscle healing in vivo. J Bone Joint Surg Br 2000; 82B: 131-137.
40. Miller K, Thaloor D, Matteson S, et al. Hepatocyte growth factor affects satellite cell activation and differentiation in regenerating skeletal muscle. Am J Physiol Cell Physiol 2000; 278: C174-C181.
41. Nikolaou P, MacDonald B, Glisson R, et al. Biomechanical and histological evaluation of muscle after controlled strain injury. Am J Sports Med 1987; 15: 9-14.
42. Huard J, Li Y, Fu F. Current concepts review, muscle injuries and repair: current trends in research. J Bone Joint Surg Am 2002; 84A: 822-832.
43. Li Y, Cummins J, Huard J. Muscle injury and repair. Curr Opin Orthop 2001; 12: 409-415.
44. Trippel S, Coutts R, Einhorn T. Growth factors as therapeutic agents. J Bone Joint Surg 1996; 78A: 1272-1286.
45. Allen R, Boxhorn L. Regulation of skeletal muscle satellite cell proliferation and differentiation by transforming growth factor-beta, insulin-like growth factor-1, and fibroblast growth factor. J Cell Physiol 1989; 138: 311-315.
46. Anderson J, Liu L, Kardami E. Distinctive patterns of basic fibroblast growth factor (bFGF) distribution in degenerative and regenerating areas of dystrophic (mdx) striated muscle. Dev Biol 1991; 147: 96-109.
47. Anderson J. Studies of the dynamics of skeletal muscle regeneration: the mouse came back. Biochem Cell Biol 1998; 76 13-26.
48. Barnard W, Bower J, Brown M, et al. Leukemia inhibitory factor (LIF) infusion stimulates skeletal muscle regeneration after injury: injured muscle expresses LIF mRNA. J Neurol Sci 1994; 123: 108-113.
49. Chambers R, McDermott J. Molecular basis of skeletal muscle regeneration. Can J Appl Physiol 1996; 21: 155-184.
50. Doumit M, Cook D, Merkel R. Fibroblast growth factor, epidermal growth factor, insulin-like growth factors, and platelet-derived growth factor-BB stimulate proliferation of clonally derived porcine myogenic satellite cells. J Cell Physiol 1993; 157: 326-332.
51. Floss T, Hans-Henning A, Braun T. A role of FGF-6 in skeletal muscle regeneration. Genes Development 1997; 11: 2040-2051.
52. Florini J, Roberts A, Ewton D, et al. Transforming growth factor-β: a very potent inhibitor of myoblast differentiation, identical to the differentiation inhibitor secreted by Buffalo rat liver cells. J Biol Chem 1986; 261: 16509-16513.
53. Gospodarowitz D, Weseman J, Moran J, et al. Effect of fibroblast growth factor on the division and fusion of bovine myoblasts. J Biol Chem 1976; 70: 395-405.
54. Grounds M. Towards understanding skeletal muscle regeneration. Path Res Pract 1991; 187: 1-22.
55. Harrington M, Daub R, Song A, et al. Interleukin 1-alpha mediated inhibition of myogenic terminal differentiation: increased sensitivity of Ha-ras transformed cultures. Cell Growth Diff 1992; 3: 241-248.
56. Jennische E, Hansson H. Regenerating skeletal muscle cells express insulin-like growth factor 1. Acta Physiol Scand 1987; 130: 327-332.
57. Jennische E. Sequential immunohistochemical expression of IGF-1 and the transferin receptor in regenerating rat muscle in vivo. Acta Endocrinol 1989; 121: 733-738.
58. Jin P, Rahm M, Claesson-Welsh L, et al. Expression of PDGF A-chain and beta-receptor genes during rat myoblast differentiation. J Cell Biol 1990; 110: 1665-1672.
59. Johnson S, Allen R. Activation of skeletal muscle satellite cells and the role of fibroblast growth factor receptors. Exp Cell Res 1995; 219: 449-453.
60. Keller H, St-Pierre Schneider B, Eppihimer L, et al. Association of IGF-1 and IGF-II with myofiber regeneration in vivo. Muscle Nerve 1999; 22: 347-354.
61. Kurek J, Bower J, Romanella M, et al. The role of leukemia inhibitory factor in skeletal muscle regeneration. Muscle Nerve 1997; 20: 815-822.
62. Lefaucheur J, Sebille A. Muscle regeneration following injury can be modified in vivo by immune neutralization of basic fibroblast growth factor, transforming growth factor β-1 or insulin-like growth factor 1. J Neuroimmunol 1995; 57: 85-91.
63. Linkhart T, Clegg C, Hauschka S. Myogenic differentiation in permanent clonal mouse myoblast cell lines: regulation by macromolecular growth factors in the culture medium. Dev Biol 1981; 86: 19-30.
64. Lyles J, Amin W, Bock E, et al. Regulation of NCAM by growth factors in serum-free myotube cultures. J Neurosci Res 1993; 34: 273-286.
65. McFarland D, Pesall J, Gilkerson K. The influence of growth factors on turkey embryonic myoblasts and satellite cells in vitro. Gen Comp Endocrinol 1993; 89: 415-424.
66. Miller K, Thaloor D, Matteson S, et al. Hepatocyte growth factor affects satellite cell activation and differentiation in regenerating skeletal muscle. Am J Physiol Cell Physiol 2000; 278: 174-181.
67. Olson E, Sterrnberg E, Hu J, et al. Regulation of myogenic differentiation by type beta transforming growth factor. J Cell Biol 1986; 103: 1799-1806.
68. Yablonka-Reuvini Z, Balestri T, Bowen-Pope D. Regulation of proliferation and differentiation of myoblasts derived from adult mouse skeletal muscle by specifc isoforms of PDGF. J Cell Biol 1990; 111: 1623-1629.
69. Damon S, Haugk K, Birnbaum R, et al. Retrovirally mediated over-expression of insulin-like growth factor is required for skeletal muscle differentiation. J Cell Physiol 1998; 175: 109-120.
70. Engert J, Berlund E, Rosenthal N. Proliferation precedes differentiation in IGF-1 stimulated myogenesis. J Cell Biol 1996; 125: 431-440.
71. Florini J, Ewton D, Falen S, et al. Biphasic concentration dependency of the stimulation of myoblast differentiation by somatomedins. Am J Physiol 1986; 250: C771-C778.
72. Quinn L, Haugk K. Over-expression of the type-1 insulin-like growth factor receptor increases ligand-dependent proliferation and differentiation in bovine skeletal myogenic cultures. J Cell Physiol 1996; 168: 34-41.
73. Florini J, Ewton D, Coolican S. Growth hormone and the insulin-like growth factor system in myogenesis. Endocr Rev 1996; 17: 481-517.
74. Zdanowicz M, Moyse J, Wingertzahn M, et al. Effect of insulin-like growth factor I in murine muscular dystrophy. Endocrinology 1995; 136: 4880-4886.
75. Coleman M, DeMayo F, Yin K, et al. Myogenic vector expression of insulin-like growth factor I stimulates muscle cell differentiation and myofiber hypertrophy in transgenic mice. J Biol Chem 1995; 270: 12 109-12 116.
76. Papdakis M, Grady D, Black D, et al. Growth hormone replacement in healthy older men improves body composition but not functional ability. Ann Int Med 1996; 124: 708-716.
77. Barton-Davis E, Shoturma D, Musaro A, et al. Viral mediated expression of insulin-like growth factor I blocks the aging-related loss of skeletal muscle function. Proc Natl Acad Sci U S A 1998; 95: 15 603-15 607.
78. Lamberts S, van den Beld A, van der Lely A. The endocrinology of aging. Science 1997; 278: 419-424.
79. Jones J, Clemmons D. Insulin-like growth factors and their binding proteins: biological actions. Endocr Rev 1995; 16: 3-34.
80. Sheehan S, Tatsumi R, Temm-Grove C, et al. HGF is an autocrine growth factor for skeletal muscle satellite cells in vitro. Muscle Nerve 2000; 23: 239-245.
81. Sheehan S, Allen R. Skeletal muscle satellite cell proliferation in response to members of the fibroblast growth factor family and hepatocyte growth factor. J Cell Physiol 1999; 181 499-506.
82. Tatsumi R, Anderson J, Nevoret C, et al. HGF/SF is present in normal adult skeletal muscle and is capable of activating satellite cells. Dev Biol 1998; 194: 114-128.
83. Springer M, Chen A, Kraft P, et al. VEGF gene delivery to muscle: potential role for vasculogenesis in adults. Mol Cell 1998; 2: 549-558.
84. Gowdak L, Poliakova L, Wang X, et al. Adenovirus-mediated VEGF(121) gene transfer stimulates angiogenesis in normoperfused skeletal muscle and preserves tissue perfusion after induction of ischemia. Circulation 2000; 102: 565-571.
85. Appleton I, Tomlinson A, Colville-Nash P, et al. Temporal and spatial immunolocalization of cytokines in murine chronic granulomatous tissue: implications for their role in tissue development and repair processes. Lab Invest 1993; 69: 405-414.
86. Barcellos-Hoff M, Derynck R, Tsang M, et al. Transforming growth factor-β activation in irradiated murine mammary gland. J Clin Invest 1994; 93: 892-899.
87. Barnes J, Abboud H. Temporal expression of autocrine growth factors corresponds to morphological features of mesangial proliferation in Habu snake venom-induced glomerulonephritis. Am J Pathol 1993; 143: 1366-1376.
88. Brandes M, Allen J, Ogawa Y, et al. Transforming growth factor β1 suppresses acute and chronic arthritis in experimental animals. J Clin Invest 1991; 87: 1108-1113.
89. Coinbra T, Wiggins R, Noh J, et al. Transforming growth factor-β production in anti-glomerular basement membrane disease in the rabbit. Am J Pathol 1991; 138: 223-234.
90. Czaja M, Weiner F, Flanders K, et al. In vitro and in vivo association of transforming growth factor-β1 with hepatic fibrosis. J Cell Biol 1989; 108: 2477-2482.
91. Jones C, Buch S, Post M, et al. Pathogenesis of interstitial fibrosis in chronic purine aminonucleoside nephrosis. Kidney Int 1991; 40: 1020-1031.
92. Kagami S, Border W, Miller D, et al. Angiotensin II stimulates extracellular matrix protein synthesis through induction of transforming growth factor-β expression in rat glomerular mesangial cells. J Clin Invest 1994; 93: 2431-2437.
93. Khalil N, Whitman C, Zuo L, et al. Regulation of alveolar macrophage transforming growth factor-β secretion by corticosteroids in bleomycin-induced pulmonary inflammation in the rat. J Clin Invest 1993; 92: 1812-1818.
94. Logan A, Berry M, Gonzalez A, et al. Effects of transforming growth factor β1 on scar production in the injured central nervous system of the rat. Eur J Neurosci 1994; 6: 355-363.
95. Okuda S, Languino L, Ruoslahti E, et al. Elevated expression of transforming growth factor-β and proteoglycan production in experimental glomerulonephritis: possible role in expansion of the mesangial extracellular matrix. J Clin Invest 1990; 86: 453-462.
96. Sporn M, Roberts A. A major advance in the use of growth factors to enhance wound healing. J Clin Invest 1993; 92: 2565-2566.
97. 1 in developing bleomycin-induced pulmonary fibrosis in rats. J Clin Invest 1993; 92: 632-637.
98. Wolf Y, Rasmussen L, Ruoslahti E. Antibodies against transforming growth factor-β1 suppress intimal hyperplasia in a rat model. J Clin Invest 1994; 93: 1172-1178.
99. Yamamoto T, Nakamura T, Noble N, et al. Expression of transforming growth factor β is elevated in human and experimental diabetic nephropathy. Proc Natl Acad Sci U S A 1993; 90: 1814-1818.
100. Bernasconi P, Torchiana E, Confalonieri P, et al. Expression of transforming growth factor-beta 1 in dystrophic patient muscles correlates with fibrosis: pathogenetic role of a fibrogenic cytokine. J Clin Invest 1995; 96: 1137-1144.
101. Yamazaki M, Minota S, Sakurai H, et al. Expression of transforming growth factor-β1 and its relation to endomysial fibrosis in progressive muscular dystrophy. Am J Pathol 1994; 14: 221-226.
102. Amemiya K, Semino-Mora C, Granger R, et al. Downregulation of TGF-β2 mRNA and protein in the muscles of patients with inflammatory myopathies after treatment with high-dose intravenous immunoglobulin. Clin Immunol 2000; 94: 99-104.
103. Confalonieri P, Bernasconi P, Cornelio F, et al. Transforming growth factor-β1 in polymyositis and dermatomyositis correlates with fibrosis but not with mononuclear cell infiltrate. J Neuropathol Exp Neurol 1997; 56: 479-484.
104. Li Y, Huard J. Differentiation of muscle-derived cells into myofibroblasts in injured skeletal muscle. Am J Pathol 2002; in press.
105. Tredget E, Wang R, Shen Q, et al. Transforming growth factor-beta mRNA and protein in hypertrophic scar tissues and fibroblasts: antagonism by IFN-alpha and IFN-gamma in vitro and in vivo. J Interferon Cytokine Res 2000; 20: 143-151.
106. Zhang L, Mi J, Yu Y, et al. IFN-gamma gene therapy by intrasplenic hepatocyte transplantation: a novel strategy for reversing hepatic fibrosis in Schistosoma japonicum-infected mice. Parasite Immunol 2001; 23: 11-17.
107. Gurujeyalakshmi G, Giri S. Molecular mechanisms of antifibrotic effect of interferon gamma in bleomycin-mouse model of lung fibrosis: downregulation of TGF-beta and procollagen I and III gene expression. Exp Lung Res 1995; 21: 791-808.
108. Oldroyd S, Thomas G, Gabbiani G, et al. Interferon-gamma inhibits experimental renal fibrosis. Kidney Int 1999; 56: 2116-2127.
109. Mietz H, Krieglstein G. Suramin to enhance glaucoma filtering procedures: a clinical comparison with mitomycin. Ophthalmic Surg Lasers 2001; 32: 358-369.
110. Kloen P, Jennings C, Gebhardt M, et al. Suramin inhibits growth and transforming growth factor-beta 1 (TGF-beta 1) binding in osteosarcoma cell lines. Eur J Cancer 1994; 30A: 678-682.
111. Zein N. Interferons in the management of viral hepatitis. Cytokines Cell Mol Ther 1998; 4: 229-241.
112. Friedlander L, van Thiel D, Faruki H, et al. New approach to HCV treatment. Recognition of disease process as systemic viral infection rather than as liver disease. Dig Dis Sci 1996; 41: 1678-1681.
113. Mankin H. The response of articular cartilage to mechanical injury. J Bone Joint Surg Am 1982; 64: 460-466.
114. Steadman J, Rodkey W, Rodrigo J. Microfracture: surgical technique and rehabilitation to treat chondral defects. Clin Orthop 2001; 39: S362-S369.
115. Brittberg M, Lindahl A, Nilsson A, et al. Treatment of deep cartilage defects in the knee with autologous chondrocyte transplantation. N Engl J Med 1994; 331: 889-895.
116. Buckwalter J, Mankin H. Articular cartilage repair and transplantation. Arthritis Rheum 1998; 41: 1331-1342.
117. Outerbridge H, Outerbridge A, Outerbridge R, et al. The use of lateral patellar autologous grafts for the repair of large osteochondral defects in the knee. Acta Orthop Belg 1999; 65 Suppl 1): 129-135.
118. Meyers M, Akeson W, Convery F. Resurfacing of the knee with fresh osteochondral allograft. J Bone Joint Surg Am 1989; 71: 704-713.
119. Radice M, Brun P, Cortivo R, et al. Hyaluronan-based biopolymers as delivery vehicles for bone-marrow-derived mesenchymal progenitors. J Biomed Mater Res 2000; 50: 101-109.
120. Martin I, Suetterlin R, Baschong W, Heberer M, Vunjak-Novakovic G, Freed LE. Enhanced cartilage tissue engineering by sequential exposure of chondrocytes to FGF-2 during 2D expansion and BMP-2 during 3D cultivation. J Cell Biochem 2001; 83: 121-128.
121. Martin I, Padera RF, Vunjak-Novakovic G, Freed LE. In vitro differentiation of chick embryo bone marrow stromal cells into cartilaginous and bone-like tissues. J Orthop Res 1998; 16: 181-189.
122. Gao J, Dennis JE, Solchaga LA, Awadallah AS, Goldberg VM, Caplan AI. Tissue-engineered fabrication of an osteochondral composite graft using rat bone marrow-derived mesenchymal stem cells. Tissue Eng. 2001; 7: 363-371.
123. Arai Y, Kubo T, Kobayashi K, et al. Adenovirus vector-mediated gene transduction to chondrocytes: in vitro evaluation of therapeutic efficacy of transforming growth factor-beta 1 and heat shock protein 70 gene transduction. J Rheumatol 1997; 24: 1787-1795.
124. Doherty P, Zhang H, Tremblay L, et al. Resurfacing of articular cartilage explants with genetically modified human chondrocytes in vitro. Osteoarthritis Cartilage 1998; 6: 153-159.
125. Smith P, Shuler F, Georgescu H, et al. Genetic enhancement of matrix synthesis by articular chondrocytes: comparison of different growth factor genes in the presence and absence of interleukin-1. Arthritis Rheum 2000; 43: 1156-1164.
126. Wehling P, Schulitz K, Robbins P, et al. Transfer of genes to chondrocytic cells of the lumbar spine. Proposal for a treatment strategy of spinal disorders by local gene therapy. Spine 1997; 22: 1092-1097.
127. Ikeda T, Kubo T, Nakanishi T, et al. Ex vivo gene delivery using an adenovirus vector in treatment for cartilage defects. J Rheumatol 2000; 27: 990-996.
128. Goomer R, Maris T, Gelberman R, et al. Nonviral in vivo gene therapy for tissue engineering of articular cartilage and tendon repair. Clin Orthop 2000; 379: S189-S200.
129. Kang R, Marui T, Ghivizzani S, et al. Ex vivo gene transfer to chondrocytes in full-thickness articular cartilage defects: a feasibility study. Osteoarthritis Cartilage 1997; 5: 139-143.
130. Baragi V, Renkiewicz R, Qiu L, et al. Transplantation of adenovirally transduced allogeneic chondrocytes into articular cartilage defects in vivo. Osteoarthritis Cartilage 1997; 5: 275-282.
131. Mason J, Grande D, Barcia M, et al. Expression of human bone morphogenic protein 7 in primary rabbit periosteal cells: potential utility in gene therapy for osteochondral repair. Gene Ther 1998; 5: 1098-1104.
132. Goomer R, Deftos L, Terkeltaub R, et al. High-efficiency non-viral transfection of primary chondrocytes and perichondrial cells for ex-vivo gene therapy to repair articular cartilage defects. Osteoarthritis Cartilage 2001; 9: 248-256.
133. Adachi N, Sato K, Usas A, et al. Muscle derived cell based ex vivo gene therapy for the treatment of full-thickness articular cartilage defects. J Rheumatol 2002; 29: 1920-1930.
134. Adachi N, Pelinkovic D, Lee C, et al. Gene therapy and the future of cartilage repair. Oper Tech Orthop 2001; 11: 138-144.
135. Miyasaka K, Daniel D, Hirschman P. The incidence of knee ligament injuries in the general population. Am J Knee Surg 1991; 4: 3-8.
136. Hawkins R, Misamore G, Merritt T. Follow up of the acute nonoperated isolated anterior cruciate ligament tear. Am J Sports Med 1986; 14: 205-210.
137. O'Donoghue D, Frank G, Jeter G, et al. Repair and reconstruction of the anterior cruciate ligament in dogs. Factors influencing long-term results. J Bone Joint Surg Am 1971; 53: 710-718.
138. Rougraff B, Shelbourne K, Gerth P, et al. Arthroscopic and histologic analysis of human patellar tendon autografts used for anterior cruciate ligament reconstruction. Am J Sports Med 1993; 21: 277-284.
139. Duffy F Jr, Seiler J, Gelberman R, et al. Growth factors and canine flexor tendon healing: initial studies in uninjured and repair models. J Hand Surg [Am] 1995; 20: 645-649.
140. Sciore P, Boykiw R, Hart D. Semiquantitative reverse transcription-polymerase chain reaction analysis of mRNA for growth factors and growth factor receptors from normal and healing rabbit medial collateral ligament tissue. J Orthop Res 1998; 16: 429-437.
141. Letson A, Dahners L. The effect of combinations of growth factors on ligament healing. Clin Orthop 1994; 308: 207-212.
142. Hildebrand K, Woo S, Smith D, et al. The effects of platelet-derived growth factor-BB on healing of the rabbit medial collateral ligament. An in vivo study. Am J Sports Med 1998; 26 549-554.
143. Lynch S, Williams R, Polson A, et al. A combination of platelet-derived and insulin-like growth factors enhances periodontal regeneration. J Clin Periodontol 1989; 16: 545-548.
144. Lynch S, de Castilla G, Williams R, et al. The effects of short-term application of a combination of platelet-derived and insulin-like growth factors on periodontal wound healing. J Periodontol 1991; 62: 458-467.
145. Gerich T, Kang R, Fu F, et al. Gene transfer to the patellar tendon. Knee Surg Sports Traumatol Arthrosc 1997; 5: 118-123.
146. Nakamura N, Horibe S, Matsumoto N, et al. Transient introduction of a foreign gene into healing rat patellar ligament. J Clin Invest 1996; 97: 226-231.
147. Nakamura N, Shino K, Natsuume T, et al. Early biological effect of in vivo gene transfer of platelet-derived growth factor (PDGF)-B into healing patellar ligament. Gene Ther 1998; 5: 1165-1170.
148. Ozkan I, Shino K, Nakamura N, et al. Direct in vivo gene transfer to healing rat patellar ligament by intra-arterial delivery of haemagglutinating virus of Japan liposomes. Eur J Clin Invest 1999; 29: 63-67.
149. Lou J, Manske P, Aoki M, et al. Adenovirus-mediated gene transfer into tendon and tendon sheath. J Orthop Res 1996; 14: 513-517.
150. Lou J, Kubota H, Hotokezaka S, et al. In vivo gene transfer and overexpression of focal adhesion kinase (pp125 FAK) mediated by recombinant adenovirus-induced tendon adhesion formation and epitenon cell change. J Orthop Res 1997; 15: 911-918.
151. Goomer R, Deftos L, Terkeltaub R, et al. High-efficiency non-viral transfection of primary chondrocytes and perichondrial cells for ex-vivo gene therapy to repair articular cartilage defects. Osteoarthritis Cartilage 2001; 9: 248-256.
152. Gerich T, Kang R, Fu F, et al. Gene transfer to the rabbit patellar tendon: potential for genetic enhancement of tendon and ligament healing. Gene Ther 1996; 3: 1089-1093.
153. Martinek V, Latterman C, Usas A, et al. Enhancement of tendon-bone integration of anterior cruciate ligament grafts with bone morphogenetic protein-2 gene transfer. J Bone Joint Surg Am. 2002; 84-A: 1123-1131.
154. Arnoczky S, Warren R. The microvasculature of the meniscus and its response to injury. An experimental study in the dog. Am J Sports Med 1983; 11: 131-141.
155. Bolano L, Grana W. Isolated arthroscopic partial meniscectomy. Functional radiographic evaluation at five years. Am J Sports Med 1993; 21: 432-437.
156. Kasemkijwattana C, Menetrey J, Goto H, et al. The use of growth factors, gene therapy and tissue engineering to improve meniscal healing. Mater Sci Eng 2000; C13: 19-28.
157. Arnoczky S, Warren R, Spivak J. Meniscal repair using an exogenous fibrin clot. An experimental study in dogs. J Bone Joint Surg Am 1988; 70: 1209-1217.
158. Shirakura K, Niijima M, Kobuna Y, et al. Free synovium promotes meniscal healing. Synovium, muscle and synthetic mesh compared in dogs. Acta Orthop Scand 1997; 68: 51-54.
159. Spindler K, Mayes C, Miller R, et al. Regional mitogenic response of the meniscus to platelet-derived growth factor (PDGF-AB). J Orthop Res 1995; 13: 201-207.
160. Jorgensen U, Sonne-Holm S, Lauridsen F, et al. Long-term follow-up of meniscectomy in athletes. A prospective longitudinal study. J Bone Joint Surg Br 1987; 69: 80-83.
161. de Boer H, Koudstaal J. Failed meniscus transplantation. A report of three cases. Clin Orthop 1994; 306: 155-162.
162. Noyes F. A histological study of failed human meniscal allografts [oral presentation]. Specialty Day, Arthroscopy Association of North America; 1995 Feb 19; Orlando, FL, USA.
163. Seneviratne A, Suzuki K, Warren R, et al. The basic biology of meniscus allograft transplantation in humans [poster presentation]. ORS 45th Annual Meeting; 1999 Feb 1-4; Anaheim, CA, USA.
164. Martinek V, Usas A, Pelinkovic D, et al. Genetics engineering of meniscal allografts. Tissue Eng 2002; 8: 107-117.
165. Cattermole H, Hardy J, Gregg P. The footballer's fracture. Br J Sports Med 1996; 30: 171-175.
166. Matheson G, Clement D, McKenzie D, et al. Stress fractures in athletes. A study of 320 cases. Am J Sports Med 1987; 15: 46-58.
167. Milgrom C, Giladi M, Chisin R, et al. The long-term follow up of soldiers with stress fractures. Am J Sports Med 1985; 13: 398-400.
168. Wright V, Peng H, Usas A, et al. BMP4 expressing muscle-derived stem cells differentiate into osteogenic lineage and improve bone healing in immunocompetent mice. Mol Ther. 2002; 6 169-178.
169. Lee J, Qu-Petersen Z, Cao B, et al. Clonal isolation of muscle-derived cells capable of enhancing muscle regeneration and bone healing. J Cell Biol 2000; 150: 1085-1100.
170. Lane J, Sandhu H. Current approaches to experimental bone grafting. Orthop Clinics North Am 1986; 18: 213-225.
171. Weiland A, Daniel R. Microvascular anastomoses for bone grafts in the treatment of massive defects in bone. J Bone Joint Surg 1979; 60: 365.
172. Urist M. Bone. Formation by autoinduction. Science 1965; 150: 895-899.
173. Wozney J, Rosen V, Celeste A, et al. Novel regulators of bone formation: molecular clones and activities. Science 1988; 242: 1528-1534.
174. Bostrom M, Lane J, Tomin E, et al. Use of bone morphogenetic protein-2 in the rabbit ulnar nonunion model. Clin Orthop 1996; 327: 272-282.
175. Wang E, Rosen V, D'Assandro J, et al. Recombinant human bone morphogenetic protein induces bone formation. Proc Natl Acad Sci USA 1990; 87: 2220-2224.
176. Nilsson O, Urist M, Dawson E, et al. Bone repair induced by bone morphogenetic protein in ulnar defects in dogs. J Bone Joint Surg 1986; 68: 635-642.
177. Heckman J, Sarasohn-Kahn J. The economics of treating tibia fractures: the cost of delayed unions. Bull Hosp Joint Dis 1997; 56: 63-72.
178. Lindholm T, Lindholm T, Alitalo I, et al. Bovine bone morphogenetic protein (bBMP) induced repair of skull trephine defects in sheep. Clin Orthop 1988; 227: 265-268.
179. Cook S, Baffes G, Wolfe M, et al. The effects of recombinant human osteogenic protein-1 on healing of large segmental bone defects. J Bone Joint Surg 1994; 76: 827-838.
180. Yasko A, Lane J, Fellinger E, et al. The healing of segmental bone defects, induced by recombinant human bone morphogenetic protein (rhBMP-2). J Bone Joint Surg 1992; 74: 659-670
181. Johnson E, Urist M, Finerman G. Bone morphogenetic protein augmentation grafting of resistant femoral nonunions. Clin Orthop 1988; 230: 257-265.
182. Johnson C, Urist M, Finerman G. Distal metaphyseal tibia nonunion: deformity and bone loss treated by open reduction, internal fixation, and human bone morphogenetic protein (hBMP). Clin Orthop 1990; 250: 234-240.
183. Johnson C, Urist M, Finerman G. Repair of segmental defects of the tibia with cancellous bone grafts augmented with human bone morphogenetic protein: a preliminary report. Clin Orthop 1988; 236: 249-257.
184. Sandhu H, Kanim L, Kabo J, et al. Effective doses of recombinant human bone morphogenetic protein-2 in experimental spinal fusion. Spine 1996; 21: 2115-2122.
185. Boden S, Moskovitz P, Morone M, et al. Video-assisted lateral intertransverse process arthrodesis. Validation of a new minimally invasive lumbar spinal fusion technique in the rabbit and non-human primate (rhesus) models. Spine 1996; 21: 2689-2697.
186. Mundy G. Regulation of bone formation by morphogenetic proteins and other growth factors. Clin Orthop 1996; 323: 24-28.
187. Heckman J, Boyan B, Aufdemorte T, et al. The use of bone morphogenetic protein in the treatment of non-union in a canine model. J Bone Joint Surg 1991; 73: 750-764.
188. Zellin G, Linde A. Treatment of segmental defects in long bone using osteopromotive membranes and recombinant human bone
189. Hammonds R Jr, Schwall R, Dudley A, et al. Bone-inducing activity of mature BMP-2b produced from a hybrid BMP-2a/2b precursor. Mol Endocrinol 1991; 5: 149-155.
190. Sampath T, Maliakai J, Hauschka P, et al. Recombinant human osteogenic protein-1 (hOP-1) induces new bone formation in vivo with a specific activity comparable with natural bovine osteogenic protein and stimulates osteoblast proliferation and differentiation in vitro. J Biol Chem 1992; 267: 20 352-20 362.
191. Sato M, Ochi T, Nakase T, et al. Mechanical tension-stress induces expression of bone morphogenetic protein (BMP-2) and BMP-4, but not BMP-6, BMP-7, and GDF-f mRNA, during distraction osteogenesis. J Bone Miner Res 1999; 14: 1084-1095.
192. Fang J, Zhu Y-Y, Smiley E, et al. Stimulation of new bone formation by direct transfer of osteogenic plasmid genes. Proc Natl Acad Sci USA 1996; 93: 5753-5758.
193. Leong L, Brickell P. Molecules in focus: bone morphogenetic protein-4. Int J Biochem Cell Biol 1996; 28: 1293-1296.
194. Sampath T, Rashka K, Doctor J, et al. Drosophila transforming growth factor beta superfamily proteins induce endochondral bone formation in mammals. Proc Natl Acad Sci U S A 1993; 90: 6004-6008.
195. Vainio S, Karavanova I, Jowett A, et al. Identification of BMP-4 as a signal mediating secondary induction between epithelial and mesenchymal tissues during early tooth development. Cell 1993; 75: 45-58.
196. Mori S, Yoshikawa H, Hashimoto J, et al. Antiangiogenic agent (TNP-470) inhibition of ectopic bone formation induced by bone morphogenetic protein-2. Bone 1998; 22: 99-105.
197. Ferguson C, Alpern E, Miclau T, et al. Does adult fracture recapitulate embryonic skeletal formation? Mech Dev 1999; 87: 57-66.
198. Nakagawa M, Kaneda T, Arakawa T, et al. Vascular endothelial growth factor (VEGF) directly enhances osteoclastic bone resorption and survival of mature osteoclasts. FEBS Lett 2000; 473: 161-164.
199. Leung D, Cachianes G, Kuang W, et al. Vascular endothelial growth factor is a secreted angiogenic mitogen. Science 1989; 246: 1306-1309.
200. Goad D, Rubin J, Wang H, et al. Enhanced expression of vascular endothelial growth factor in human SaOS-2 osteoblast-like cells and murine osteoblasts induced by insulin-like growth factor I. Endocrinology 1996; 137: 2262-2268.
201. Gerber H, Vu T, Ryan A, et al. VEGF couples hypertrophic cartilage remodeling, ossification and angiogenesis during endochondral bone formation. Nat Med 1999; 5: 623-628.
202. Hidaka M, Stanford W, Bernstein A. Conditional requirement for the Flk-1 receptor in the in vitro generation of early hematopoietic cells. Proc Natl Acad Sci U S A 1999; 96: 7370-7375.
203. Mitola S, Sozzani S, Luini W, et al. Tat-human immunodeficiency virus-1 induces human monocyte chemotaxis by activation of vascular endothelial growth factor receptor-1. Blood 1997; 90 1365-1372.
204. Peng H, Wright V, Usas A, et al. VEGF enhances bone formation and bone healing elicited by genetically engineered muscle derived stem cells expressing BMP-4. J Clin Invest. 2002; 110 751-759.
205. Alden T, Pittman D, Hankins G, et al. In vivo endochondral bone formation using a bone morphogenetic protein 2 adenoviral vector. Hum Gene Ther 1999; 10: 2245-2253.
206. Baltzer A, Lattermann C, Whalen J, et al. Genetic enhancement of fracture repair: healing of an experimental segmental defect by adenoviral transfer of the BMP-2 gene. Gene Ther 2000; 7: 734-739.
207. Musgrave D, Bosch P, Ghivizzani S, et al. Adenovirus-mediated direct gene therapy with bone morphogenetic protein-2 produces bone. Bone 1999; 24: 541-547.
208. Okubo Y, Bessho K, Fujimura K, et al. Osteoinduction by bone morphogenetic protein-2 via adenoviral vector under transient immunosuppression. Biochem Biophys Res Commun 2000; 267: 382-387.
209. Fang J, Zhu Y, Smiley E, et al. Stimulation of new bone formation by direct transfer of osteogenic plasmid genes. Proc Natl Acad Sci U S A 1996; 93: 5753-5758.
210. Bonadio J, Smiley E, Patil P, et al. Localized, direct plasmid gene delivery in vivo: prolonged therapy results in reproducible tissue regeneration. Nat Med 1999; 5: 753-759.
211. Morley P, Whitfield J, Willick G. Design and applications of parathyroid hormone analogues. Curr Med Chem 1999; 6: 1095-1106.
212. Goldstein S, Bonadio J. Potential role for direct gene transfer in the enhancement of fracture healing. Clin Orthop 1998; 355: S154-S162.
213. Beresford J. Osteogenic stem cells and the stromal system of bone and marrow. Clin Orthop 1989; 240: 270-280.
214. Bruder S, Kraus K, Goldberg V, et al. The effect of implants loaded with autologous mesenchymal stem cells on the healing of canine segmental bone defects. J Bone Joint Surg Am 1998; 80: 985-996.
215. Bruder S, Kurth A, Shea M, et al. Bone regeneration by implantation of purified, culture-expanded human mesenchymal stem cells. J Orthop Res 1998; 16: 155-162.
216. Lieberman J, Daluiski A, Stevenson S, et al. The effect of regional gene therapy with bone morphogenetic protein-2-producing bone-marrow cells on the repair of segmental femoral defects in rats. J Bone Joint Surg Am 1999; 81: 905-917.
217. Gazit D, Turgeman G, Kelley P, et al. Engineered pluripotent mesenchymal cells integrate and differentiate in regenerating bone: a novel cell-mediated gene therapy. J Gene Med 1999; 1: 121-133.
218. Turgeman G, Pittman DD, Muller R, et al. Engineered human mesenchymal stem cells: a novel platform for skeletal cell mediated gene therapy. J Gene Med 2001; 3: 240-251.
219. Viggeswarapu M, Boden S, Liu Y, et al. Adenoviral delivery of LIM mineralization protein-1 induces new-bone formation in vitro and in vivo. J Bone Joint Surg Am 2001; 83A: 364-376.
220. Franceschi R, Wang D, Krebsbach P, et al. Gene therapy for bone formation: in vitro and in vivo osteogenic activity of an adenovirus expressing BMP7. J Cell Biochem 2000; 78: 476-486.
221. Krebsbach P, Gu K, Franceschi R, et al. Gene therapy-directed osteogenesis: BMP-7-transduced human fibroblasts form bone in vivo. Hum Gene Ther 2000; 11: 1201-1210.
222. Fattah H, Halawa E, Shafy T. Non-union of the humeral shaft: a report on 25 cases. Injury 1982; 14: 255-262.
223. Zuk P, Zhu M, Mizuno H, et al. Multilineage cells from human adipose tissue: implications for cell-based therapies. Tissue Eng 2001; 7: 211-228.
224. Dragoo J, Choi J, Lieberman J, et al. Bone induction in BMP-2 transduced stem cells from human fat. J Bone Miner Res 2002; submitted.
225. Qu-Petersen Z, Deasy B, Jankowski R, et al. Identification of a novel population of muscle stem cells in mice: potential for muscle regeneration. J Cell Biol 2002; 157: 851-864
226. Lee J, Musgrave D, Pelinkovic D, et al. Effect of bone morphogenetic protein-2-expressing muscle-derived cells on healing of critical-sized bone defects in mice. J Bone Joint Surg Am 2001; 83A: 1032-1039.
227. Bosch P, Musgrave D, Lee J, et al. Osteoprogenitor cells within skeletal muscle. J Orthop Res 2000; 18: 933-944.
228. Deasy B, Jankowski R, Huard J. Muscle-derived stem cells: characterization and potential for cell-mediated therapy. Blood Cells Mol Dis 2001; 27: 924-933.
229. Evans C, Robbins P, Ghivizzani S, et al. Clinical trial to assess the safety, feasibility, and efficacy of transferring a potentially anti-arthritic cytokine gene to human joints with rheumatoid arthritis. Hum Gene Ther 1996; 7: 1261-1280.
230. Moutsatsos IK, Turgeman G, Zhou S, et al. Exogenously regulated stem cell-mediated gene therapy for bone regeneration. Mol Ther 2001; 3: 449-461.